Get the Stockscreener App
2.25
5.86%
-0.14
After Hours:
2.15
-0.10
-4.44%
Gri Bio Inc stock is traded at $2.25, with a volume of 107.06K.
It is down -5.86% in the last 24 hours and down -66.79% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$2.39
Open:
$2.44
24h Volume:
107.06K
Relative Volume:
0.30
Market Cap:
$3.25M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.042
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
+2.74%
1M Performance:
-66.79%
6M Performance:
-93.65%
1Y Performance:
-99.14%
1-Day Range:
$2.10
$2.44
1-Week Range:
$2.10
$2.53
52-Week Range:
$2.10
$311.36
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
2.25 | 3.45M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio: Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum - TradingView
GRI Bio: Positive phase 2A IPF data and pipeline progress position GRI Bio for key upcoming milestones - TradingView
Levels Update: Is now the right time to enter SHF Holdings IncPortfolio Value Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Yahoo Finance
GRI Bio reports $8.2 million cash position, extends runway into Q1 2027 - Investing.com Canada
GRI Bio sees cash runway into 1Q27 - TipRanks
GRI Bio raises $14.5 mln to fund operations into Q1 2027 - TradingView
GRI Bio: Strong cash position and positive clinical data support continued pipeline advancement - TradingView
GRI Bio, Inc. Reports Strong Cash Position and Positive Phase 2a Results for GRI-0621 in Pulmonary Fibrosis - Quiver Quantitative
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
GRI Bio (GRI) Price Target Increased by 2,700.00% to 656.88 - Nasdaq
Jobs Data: Will Predictive Oncology Inc benefit from rising consumer demandPortfolio Performance Report & Comprehensive Market Scan Insights - baoquankhu1.vn
Dip Buying: Is CALX forming bullish engulfing patternsForecast Cut & Free Reliable Trade Execution Plans - baoquankhu1.vn
Aug Summary: What makes GRI Bio Inc stock attractive todayJuly 2025 Rallies & Low Drawdown Trading Techniques - baoquankhu1.vn
Trading Recap: Can OACCU deliver consistent dividendsJuly 2025 Final Week & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Gri Bio Warns of Ongoing Internal Control Weaknesses That Could Threaten Financial Reporting Reliability and Investor Confidence - TipRanks
Rate Cut: Is GRI Bio Inc forming a double bottomQuarterly Portfolio Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Buyback Watch: Is JVSPAC Acquisition Corp Equity Right a momentum stockEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
GRI Bio: 2025 net loss rose to $12M as R&D spending increased; more capital needed for future trials - TradingView
GRI Bio, Inc. SEC 10-K Report - TradingView
GRI Bio Expands At-The-Market Equity Offering Capacity - TipRanks
GRI Bio May Offer Up To $250 Million In SecuritiesSEC Filing - TradingView
Movement Recap: Can GRI Bio Inc be recession proof2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
GRI Bio (GRI) expands at-the-market equity program to $60M capacity - Stock Titan
GRI Bio reports positive gene expression data for IPF drug candidate - Investing.com Nigeria
What’s the RSI of GRI Bio Inc. stockQuarterly Portfolio Review & AI Forecasted Stock Moves - mfd.ru
GRI Bio delivers additional data from Phase 2a study of GRI-0621 - TipRanks
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Asianet Newsable
GRI Bio Reports New Phase 2a Gene Expression Data Supporting Anti-Fibrotic Activity Of GRI-0621 - Nasdaq
GRI Bio reports promising Phase 2a data in IPF - TipRanks
GRI Bio stock soars after gene data shows IPF drug targets disease drivers - Investing.com Nigeria
GRI Bio stock soars after gene data shows IPF drug targets disease drivers By Investing.com - Investing.com South Africa
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
GRI Bio, Inc. Reports Positive Phase 2a Results for GRI-0621 as Disease-Modifying Therapy in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Early lung fibrosis trial hints drug may help repair damaged lung tissue - stocktitan.net
Market Leaders: Can Docebo Inc weather a recessionWeekly Trade Summary & Consistent Income Trade Recommendations - baoquankhu1.vn
GRI Bio secures U.S. composition of matter patent - TipRanks
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - GlobeNewswire
Trade Recap: Is DB Gold Double Short ETN stock a buy or sellTrade Signal Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Analysis Recap: Can Viavi Solutions Inc withstand a market correction2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Trade Report: Is GRI Bio Inc in a long term uptrendNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
GRI Bio To Carry Out 1-for-28 Reverse Stock Split On January 26th, 2026 - 富途牛牛
GRI Bio announces 1-for-28 reverse stock split to regain Nasdaq compliance - Investing.com Nigeria
GRI Bio stock falls after announcing 1-for-28 reverse split - Investing.com India
GRI Bio Announces Reverse Stock Split To Regain Minimum Bid Price Nasdaq Compliance - Nasdaq
Gri Bio Announces Reverse Stock Split - TradingView
GRI Bio Announces 1-for-28 Reverse Stock Split - TipRanks
GRI Bio stock falls after announcing 1-for-28 reverse split By Investing.com - Investing.com South Africa
GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - stocktitan.net
GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan
GRI Bio Announces Reverse Stock Split - marketscreener.com
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):